Evidence map›Paper›PMID 28644696›Full record

ReviewExpert review of vaccines2017

Varicella vaccination - the global experience.

Peter Wutzler, Paolo Bonanni, Margaret Burgess, Anne Gershon, Marco Aurélio Sáfadi, Giacomo Casabona

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of vaccines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 7 pooled it
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 7 syntheses or guidelines pooled it, 174 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Vaccines for measles, mumps, rubella, and varicella in children.The Cochrane database of systematic reviews · 2021
    Pooled it
  5. Vaccines for measles, mumps, rubella, and varicella in children.The Cochrane database of systematic reviews · 2020
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Varicella zoster virus and the central nervous system.Nature reviews. Microbiology · 2026
    Review
  19. Article
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 5 countries.

Peter Wutzlera Institute of Virology and Antiviral Therapy , Friedrich Schiller University , Jena , Germany.
Paolo Bonannib Department of Health Sciences , University of Florence , Florence , Italy.ORCID 0000-0003-2875-3744
Margaret Burgessc The Discipline of Paediatrics and Adolescent Health , University of Sydney , Sydney , Australia.
Anne Gershond Division of Infectious Disease , Columbia University , New York , NY , USA.
Marco Aurélio Sáfadie Department of Pediatrics , Santa Casa de Sao Paulo School of Medical Sciences , Sao Paulo , Brazil.
Giacomo Casabonaf Global Medical Affairs Rota & MMRV, GSK , Wavre , Belgium.
Columbia University · USFaculdade de Ciências Médicas da Santa Casa de São Paulo · BRFriedrich Schiller University Jena · DEThe University of Sydney · AUUniversity of Florence · IT

Funding

VZV in the enteric nervous system: pathogenesis and consequencesR01DK093094 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MICHAEL D GERSHON, Anne A. Gershon · 2011 to 2026
$5.9M
NIDDK NIH HHS R01 DK093094
6 · The paper itself

Abstract

introductionVaricella, although a frequently benign childhood disease, nevertheless represents a considerable health burden. WHO recommends including varicella vaccines in universal routine vaccination programs, and maintaining coverage >80%. Many countries have successfully introduced varicella vaccination and have benefited from lower disease burden, but many others have not adopted the vaccine. Reasons include cost commitment for a 'mild childhood disease' or concerns that vaccination will shift varicella to older age groups or increase herpes zoster incidence. Areas covered: This literature review summarizes the effectiveness and epidemiological impact of varicella immunization programs. Expert commentary: Varicella vaccines are immunogenic with acceptable safety profiles. One and two dose schedules are highly effective against varicella and large reductions in disease incidence, particularly moderate-severe disease, have been widely reported. There is currently no evidence to suggest that the introduction of varicella vaccination results in a shift of varicella disease burden to older age groups. Although epidemiological studies have shown an increased incidence of herpes zoster since the vaccines were launched, there are many other contributing factors, and indeed, this secular trend was evident before their introduction. In conclusion, varicella vaccination easily fits into existing immunization programs and significantly reduces the often underestimated burden of varicella.

Indexed as

Vaccination CoverageChickenpoxChickenpox VaccineDrug-Related Side Effects and Adverse ReactionsGlobal HealthHerpes ZosterHumansImmunization ScheduleChickenpox Vaccineeffectivenessherpes zosterimmunizationvaccinesVaricella

Identifiers

PMID28644696
PMCPMC5739310
OpenAlexW2722561850

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.